Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.
Excellent balance sheet and fair value.
Share Price & News
How has Calithera Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2CB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2CB exceeded the German Biotechs industry which returned -2.9% over the past year.
Return vs Market: 2CB exceeded the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is Calithera Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Calithera Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2CB (€6.2) is trading below our estimate of fair value (€21.22)
Significantly Below Fair Value: 2CB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2CB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2CB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2CB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2CB is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (3.2x).
How is Calithera Biosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2CB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2CB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2CB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2CB's revenue (55.7% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 2CB's revenue (55.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2CB's Return on Equity is forecast to be high in 3 years time
How has Calithera Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2CB is currently unprofitable.
Growing Profit Margin: 2CB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2CB is unprofitable, and losses have increased over the past 5 years at a rate of -23.8% per year.
Accelerating Growth: Unable to compare 2CB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2CB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 2CB has a negative Return on Equity (-72.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Calithera Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: 2CB's short term assets ($136.8M) exceed its short term liabilities ($18.5M).
Long Term Liabilities: 2CB's short term assets ($136.8M) exceed its long term liabilities ($7.2M).
Debt to Equity History and Analysis
Debt Level: 2CB is debt free.
Reducing Debt: 2CB has not had any debt for past 5 years.
Inventory Level: 2CB has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 2CB's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2CB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2CB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Calithera Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 2CB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2CB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2CB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2CB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2CB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Susan Molineaux (65yo)
Dr. Susan M. Molineaux, Ph.D., Co-founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and President since June 2010. She focuses on Biopharmaceuticals. Dr. Molineaux a ...
CEO Compensation Analysis
Compensation vs Market: Susan's total compensation ($USD2.03M) is above average for companies of similar size in the German market ($USD811.49K).
Compensation vs Earnings: Susan's compensation has increased whilst the company is unprofitable.
|Chief Business Officer||1.1yrs||US$883.44k||0.044% $141.5k|
|Chief Medical Officer||3.8yrs||US$1.14m||0.016% $51.6k|
|Senior VP of Finance & Secretary||0yrs||no data||0.079% $255.4k|
|Vice President of Investor Relations & Strategy||3.2yrs||no data||no data|
|Senior VP||2.3yrs||US$1.26m||no data|
|Head of People & Culture||0yrs||no data||no data|
|Senior Vice President of Drug Discovery||9.7yrs||US$959.51k||0.13% $435.1k|
|Senior Vice President of Development||6.8yrs||US$446.60k||0.0046% $15.1k|
|Senior Vice President of Clinical Development||1.1yrs||no data||no data|
Experienced Management: 2CB's management team is considered experienced (3.5 years average tenure).
|Independent Director||7.4yrs||US$98.30k||no data|
|Independent Director||5.2yrs||US$97.30k||no data|
|Lead Independent Director||3.1yrs||US$120.30k||no data|
|Independent Director||6.2yrs||US$87.30k||no data|
|Independent Director||4.4yrs||US$93.80k||no data|
|Independent Director||3.5yrs||US$89.80k||0.013% $43.4k|
Experienced Board: 2CB's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.1%.
Calithera Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Calithera Biosciences, Inc.
- Ticker: 2CB
- Exchange: DB
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$357.068m
- Listing Market Cap: US$324.682m
- Shares outstanding: 53.78m
- Website: https://www.calithera.com
Number of Employees
- Calithera Biosciences, Inc.
- 343 Oyster Point Boulevard
- Suite 200
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CALA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2014|
|2CB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2014|
|2CB||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Oct 2014|
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 22:38|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.